Recent advances in haematology and oncology: graft-versus-host disease, classification and treatment of non-Hodgkin's lymphomas, and sentinel-node biopsy in breast cancer
K. A. Finucane,
C. B. Archer,
K. A. Finucane
Bristol Royal Infirmary, Dermatology, Bristol, UK
Search for more papers by this authorK. A. Finucane,
C. B. Archer,
K. A. Finucane
Bristol Royal Infirmary, Dermatology, Bristol, UK
Search for more papers by this authorFirst published: 28 September 2005
Dr Katherine Finucane, Bristol Royal Infirmary (UBHT), Dermatology, Bristol BS2 8HW, UK.
E-mail: [email protected]
Conflict of interest: none declared.
References
- 1 Higman M, Vogelsang G. Chronic graft versus host disease. Br J Haematol 2004; 125: 435–54.
- 2 Vargas-Díez E, Fernãndez-Herrara J, Marin A et al. Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation. Br J Dermatol 2003; 148: 1129–34.
- 3 Gilliam A. Update on graft versus host disease. J Invest Dermatol 2004; 123: 251–7.
- 4 International Bone Marrow Registry. http://www.ibmtr.org
- 5 Hofmeister C, Quinn A, Cooke K et al. Graft-versus-host disease of the skin: Life and death on the epidermal edge. Biol Bone Marrow Transplantation 2004; 10: 366–72.
- 6 Appelbaum F. The current status of haematopoietic cell transplantation. Ann Rev Med 2003; 54: 491–512.
- 7 Davies J, Lowdell M. New advances in acute graft-versus-host disease prophylaxis. Transfusion Med 2003; 13: 387–97.
- 8 Zeiser R, Marks R, Betz H et al. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventative and therapeutic strategies. Ann Hematol 2004; 83: 551–65.
- 9 Marra D, McKee P, Nghiem P. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. J Am Acad Dermatol 2004; 51: 543–6.
- 10 Vassallo C, Brazzelli V, Alessandrino P et al. Normal-looking skin in oncohaematological patients after allogenic bone marrow transplantation is not normal. Br J Dermatol 2004; 151: 579–86.
- 11 Gilman AL, study chair. Hydroxychloroquine in treating patients with newly diagnosed chronic graft-versus-host disease. Clinical trial recruiting information. 2003. http://clinicaltrials.gov/ct/show/NCT00031824?order=2. Accessed 30 June 2005.
- 12 Cheson BD. What is new in lymphoma? Ca Cancer J Clin 2004; 54: 260–72.
- 13 Russell-Jones R. World Health Organisation classification of hematopoietic and lymphoid tissues: Implications for dermatology. J Am Acad Dermatol 2003; 48: 93–102.
- 14 National Institute for Clinical Excellence. Full guidance on rituximab for aggressive non-Hogkin's lymphoma, 2003. http://www.nice.org.uk.
- 15
Winter J,
Gascoyne R,
Van Besien K.
Low-grade lymphoma.
Hematology
2004; 1: 203.
10.1182/asheducation-2004.1.203 Google Scholar
- 16
Fisher R,
Miller T,
O'Connor O.
Diffuse aggressive lymphoma.
Hematology
2004; 1: 221.
10.1182/asheducation-2004.1.221 Google Scholar
- 17 Kim, R, Emi M, Tanabe K, Toge T. Therapeutic potential of anti-sense Bcl-2 as a chemosensitiser for cancer therapy. Cancer 2004; 101: 2491–502.
- 18 Kuerer H, Newman L. Lymphatic mapping and sentinel node biopsy for breast cancer: developments and resolving controversies. J Clin Oncol 2005; 23: 1698–705.
- 19 Veronesi U, Galimberti V, Mariani L et al. Sentinel node biopsy in breast cancer; early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 2005; 41: 231–7.
- 20 Ronka R, Von Smitten K, Tasmuth T et al. One-year morbidity after sentinel node biopsy and breast surgery. Breast 2005; 14: 28–36.
